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rituximab, following the failure of one previous TNF inhibitor.
Upon treatment failure it was assumed patients would follow an
identical lifetime treatment strategy consisting of: leﬂunomide,
gold, cyclosporine and palliative care. As is currently recom-
mended by NICE no second TNF inhibitor was assumed to be
administered. Rituximab was assumed to be administered every
9 months for responding patients. ACR response rates were
taken from the respective phase III RCTs and adjusted for
placebo response. The initial HAQ drop by ACR category was
taken from the REFLEX RCT, with long-term HAQ progression
from published literature. RESULTS: Annual drug acquisition
and administration costs were lower for rituximab compared to
abatacept. Discounted total lifetime direct NHS costs were
£46,570 and £63,055 for the rituximab and abatacept groups
respectively. Rituximab generated a discounted cost-saving of
£16,485 per patient due to reduced drug acquisition and admin-
istration costs. Total QALYs were estimated as 3.879 and 3.812
for rituximab and abatacept, respectively. CONCLUSION: The
model predicted that rituximab dominated abatacept for RA
patients who have failed one previous TNF inhibitor therapy,
with higher estimated QALYs and lower NHS costs. Due to
lower drug administration requirements rituximab may also gen-
erate a capacity beneﬁt to the NHS compared with abatacept,
through lower annual infusion and outpatient requirements.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoim-
mune disorder associated with substantial health and economic
burden. We describe a cost-utility model developed to assess the
cost-utility of Abatacept in the treatment of RA in the UK (NHS).
METHODS: A probabilistic patient level simulation model was
developed to estimate long-term costs and health outcomes of
abatacept versus methotrexate (MTX) in RA patients who failed
anti-TNF therapy. The model predicted patients’ HAQ (Health
Assessment Questionnaire) scores over time based on the initial
response to treatment (% change in HAQ at six months).
Patients with an inadequate response (failure to achieve a speci-
ﬁed reduction in HAQ score) ended treatment at this point.
Responding patients continued treatment with a reduced rate of
HAQ progression until long-term treatment failure—modelled as
an exponential process. On long term treatment failure, patients’
HAQ was assumed to worsen by amount equal to their initial
improvement. Efﬁcacy and adverse events rates were obtained
from a randomized clinical trial. Costs, utility and annual mor-
tality rates (AMR) were estimated as a function of HAQ.
RESULTS: Compared to MTX, Abatacept treatment results in
1.6 additional QALYs at an additional cost of £40,371, giving an
ICER of £25,395/QALY, a value in line with other biologic
treatments recommended for use in the UK. Results were stable
under a range of sensitivity analyses. CONCLUSION: Compared
to MTX, Abatacept is a cost-effective treatment for patients who
failed anti-TNF therapy. The use of a patient level simulation
allows costs and utilities to be estimated as non-linear functions
of HAQ and for the AMR to be conditioned on patient’s HAQ
scores. The model was implemented in R and was sufﬁciently fast
for probabilistic analysis. This allowed two key requirements for
decision-making to be met: unbiased estimates of costs and
effects and an assessment of the decision uncertainty.
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OBJECTIVES: The targeted B-cell therapy rituximab (RTX) is
registered for patients with rheumatoid arthritis (RA) who have
had inadequate response or intolerance to one or more TNF-
alpha blocking agents. The only third payer in Hungary, the
National Health Insurance Found required economic data about
RTX treatment for reimbursement decision. The aim of our study
was to estimate the cost-effectiveness of RTX in Hungarian
context in RA patients who failed anti-TNF therapy.
METHODS: We developed a Markov model to perform a cost-
utility analysis. Cost per quality adjusted life year (QALY) gain
was assessed. RTX was compared with traditional treatment
(DMARDs) in the model. Model states were deﬁned by ACR
responses. Baseline characteristics of the patient population and
clinical efﬁcacy were based on international data, the REFLEX
trial. Costs of rituximab (drug therapy, administration and moni-
toring) were calculated based on ofﬁcial Hungarian price list. RA
related costs were taken from a previous Hungarian cost-of-
illness study considering disease levels by HAQ. Utility was
derived using the equation between HAQ and EQ-5D from a
Hungarian survey of RA patients. The time horizon of the model
was lifetime. Cost effectiveness analysis was performed for one
year RTX treatment. The model used a societal perspective
including all costs. RESULTS: One year long RTX treatment (9
month between courses) results in 0.228 QALY gain compared
with traditional treatment in lifetime perspective. Incremental
total costs were 6,224 Euros, cost-effectiveness ratio was 27,258
Euros/QALY. Cost-effectiveness of two years long RTX treat-
ment is 23,182 Euros/QALY. Increasing the duration of treat-
ment resulted better cost-effectiveness ratio. CONCLUSION:
Cost-effectiveness of RTX is under the commonly used ﬁnancing
threshold (30,000€/QALY), although RTX was compared with
low cost traditional treatment. Hungarian cost-effectiveness ratio
may be higher than the European average because drug costs are
comparable but medical costs are lower in Hungary than in the
EU.
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OBJECTIVES: Evaluate the impact of persistence with anti-TNF
treatment on total health care and medical costs among patients
with psoriatic arthritis (PsA). METHODS: A retrospective study
was conducted using the US PharMetrics managed-care-plan
database from January 2000 through June 2005. Patients con-
tinuously enrolled for 6 months pre- and 12 months post-index
biologic date and having 2 distinct claims for PsA were included.
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Persistence rate (%) was deﬁned as the number of days between
ﬁrst biologic prescription and last biologic encounter, divided by
365 and multiplied by 100. Two mutually exclusive cohorts
were deﬁned based on their persistence rates: patients with per-
sistence >=80% and patients with persistence <80%. Total
health care and medical costs were assessed during the study
period. Per patient per month (PPPM) costs were calculated.
Cost of adverse events could not be identiﬁed separately in this
analysis. A multivariate model was used to adjust for covariates
including age, gender, Charlson Co-morbidity Index (CCI), and
pre-index period health care costs. RESULTS: In all, 358
patients were included, 206 (57.5%) with a persistence rate
<80% and 152 (42.5%) with a persistence rate >=80%. Nearly
half were female and the mean age was 45.2 years. The higher
persistence cohort had lower PPPM medical costs ($359.54
versus $407.14) and total health care costs ($1541.56 versus
$2653.30) compared with the lower persistence cohort. Also,
the multivariate analysis indicated that after adjusting for the
confounding factors: age, gender, CCI, and pre-index period
health care costs, a higher persistence rate is signiﬁcantly asso-
ciated with lower total health care PPPM costs (P < 0.0001).
CONCLUSION: A higher persistence rate with anti-TNF
therapy is associated with lower health care costs. Future studies
to examine the impact of persistence with anti-TNF therapy
on clinical and humanistic outcomes in patients with PsA are
recommended.
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OBJECTIVES: On September 30, 2004, rofecoxib—a drug used
to treat inﬂammation—was voluntarily withdrawn from the US
market due to mounting evidence of increased cardiovascular
(CV) risk. This study sought to assess movement in the number
of clinically appropriate (CAP) cyclo-oxygenase (COX)-2
prescriptions dispensed after the rofecoxib withdrawal; and
whether patients with CAP proﬁles demonstrated different post-
withdrawal switching behavior or incurred different levels of
health care costs. METHODS: Administrative claims data from
four regional health plans were used. To examine differences in
clinically appropriate prescribing pre- and post-rofecoxib with-
drawal, a generalized estimating equations approach was used.
RESULTS: Based on a total of 317,762 prescriptions, this study
found that CAP prescribing rates were lower after news of the
increased drug risk, as were the total number of COX-2 prescrip-
tions that were clinically inappropriate. Patients with CAP risk
were more likely to exhibit switching behavior by ﬁlling prescrip-
tions for nonselective (ns) NSAIDs or discontinuing use of all
NSAIDs. Health care costs incurred in the year following the
rofecoxib withdrawal were lower for patients who were pre-
scribed COX-2s appropriately. CONCLUSION: These ﬁndings
suggest that the widespread coverage of the rofecoxib with-
drawal, which led to heightened awareness of the drug’s risk
affected consumer demand for COX-2s and may have had unin-
tended consequences in reducing the number of patients who
“should have been” receiving these medications according to
clinical risk. Because patients and physicians were forced to make
a medical decision under risk, increased information of the
beneﬁt-risk tradeoff may have been helpful and may have con-
tributed to greater consumer welfare.
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OBJECTIVES: Pharmacovigilance is a very important tool for
registration authorities and pharmaceutical industries to gather
extra information on effectiveness and adverse effects of widely
used drugs. Therefore, post-marketing research can lead to new
insights on therapeutic usability and consequently changes
in registration ﬁles or even result in market withdrawal. In
September 2004, rofecoxib was withdrawn from the market for
reasons of serious cardiovascular adverse events. Our objective
was to evaluate trends in market-share and expenditures of
cyclooxygenase-2 (cox-2) selective and non-selective NSAIDs
around market withdrawal of rofecoxib. METHODS: Analyses
were conducted using pharmacy prescription data from IADB.nl
(50 pharmacies), covering a Dutch population of 500,000 sub-
jects. NSAID-use was calculated per 10,000 of the population
and presented quarterly from 2000–2006. Expenditures related
to NSAID-use were calculated and presented in costs per 1000 of
the population. RESULTS: After market introduction of cox-2
selective NSAIDs, proportional use increased to a maximum of
17% in the third quarter of 2004. After market withdrawal of
rofecoxib, the number of subjects receiving celecoxib and etori-
coxib increased enormously (from 22 to 48 and 18 to 28 subjects
per 10,000 population, respectively), but decreased shortly there-
after. Similar results were found for new users. After market
withdrawal, costs per 1000 population decreased with 65% and
24% for cox-2 selective and the total group of NSAIDs, respec-
tively. During additional study follow-up, costs per DDD were
generally increasing for cox-2 selective and decreasing for other
NSAIDs. Further results will be presented on switching patterns
from rofecoxib to other NSAIDs, with a speciﬁc focus on con-
comitant use of proton-pump-inhibitors for gastrointestinal pro-
tection and related extra costs. CONCLUSION: Withdrawal of
rofecoxib from the Dutch market resulted in a decreasing
number of subjects receiving cox-2 selective NSAIDs (class-
effect) and lower expenditures for the whole group of NSAIDs.
Further research is currently conducted to complete the full eco-
nomic picture.
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OBJECTIVES: The pharmacological prescription can present
geographical variation due to multiple factors. The aim of this
communication is to introduce the spatial variability in the evalu-
ation of different individual outcomes. METHODS: Pharmaco-
logical prescription data of 10,410 persons with diagnosis of
osteoarthrosis were analyzed. The prescriptions were fulﬁlled
during the year 2006 in the health department 11 of the Comu-
nitat Valenciana (Spain). The number of recipes, the number of
prescribed principles and the pharmaceutical expense for every
patient were evaluated. The relationship with gender and age was
explored by means of generalized linear models. The geographi-
cal variation between different administrative units is introduced
by means of heterogeneity and structured random effects. The
proposed hierarchical models were analyzed using Bayesian
methods with MCMC procedures. RESULTS: Models with
random spatial effects explain an important part of the variabil-
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